These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 12438957)

  • 21. A United States compassionate use study of lamivudine treatment in nontransplantation candidates with decompensated hepatitis B virus-related cirrhosis.
    Hann HW; Fontana RJ; Wright T; Everson G; Baker A; Schiff ER; Riely C; Anschuetz G; Gardner SD; Brown N; Griffiths D;
    Liver Transpl; 2003 Jan; 9(1):49-56. PubMed ID: 12514773
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Beneficial effect of lamivudine in recurrent hepatitis B after liver transplantation.
    Ben-Ari Z; Shmueli D; Mor E; Shapira Z; Tur-Kaspa R
    Transplantation; 1997 Feb; 63(3):393-6. PubMed ID: 9039929
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A study on efficacy of lamivudine therapy in decompensated cirrhosis of liver due to chronic hepatitis B virus infection.
    Sharma YR; Miah AR; Saha SK; Mohammed S; Rahman M; Roy PK; Hasan M
    Nepal Med Coll J; 2004 Dec; 6(2):106-11. PubMed ID: 16295739
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Outcomes of patients with hepatitis B who developed antiviral resistance while on the liver transplant waiting list.
    Osborn MK; Han SH; Regev A; Bzowej NH; Ishitani MB; Tran TT; Lok AS;
    Clin Gastroenterol Hepatol; 2007 Dec; 5(12):1454-61. PubMed ID: 17977800
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term lamivudine monotherapy prevents development of hepatitis B virus infection in hepatitis B surface-antigen negative liver transplant recipients from hepatitis B core-antibody-positive donors.
    Prakoso E; Strasser SI; Koorey DJ; Verran D; McCaughan GW
    Clin Transplant; 2006; 20(3):369-73. PubMed ID: 16824156
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Successful treatment with tenofovir in a child C cirrhotic patient with lamivudine-resistant hepatitis B virus awaiting liver transplantation. Post-transplant results.
    Taltavull TC; Chahri N; Verdura B; Gornals J; Lopez C; Casanova A; Cañas C; Figueras J; Casais LA
    Transpl Int; 2005 Jul; 18(7):879-83. PubMed ID: 15948869
    [TBL] [Abstract][Full Text] [Related]  

  • 27. New era of liver transplantation for hepatitis B: a 17-year single-center experience.
    Anselmo DM; Ghobrial RM; Jung LC; Weaver M; Cao C; Saab S; Kunder G; Chen PW; Farmer DG; Yersiz H; Baquerizo A; Geevarghese S; Han SH; Goldstein L; Holt CD; Gornbein JA; Busuttil RW
    Ann Surg; 2002 May; 235(5):611-9; discussion 619-20. PubMed ID: 11981206
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Improvements in parameters of end-stage liver disease in patients with HIV/HBV-related cirrhosis treated with tenofovir.
    Matthews GV; Cooper DA; Dore GJ
    Antivir Ther; 2007; 12(1):119-22. PubMed ID: 17503756
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Genotypic and phenotypic resistance: longitudinal and sequential analysis of hepatitis B virus polymerase mutations in patients with lamivudine resistance after liver transplantation.
    Ben-Ari Z; Daudi N; Klein A; Sulkes J; Papo O; Mor E; Samra Z; Gadba R; Shouval D; Tur-Kaspa R
    Am J Gastroenterol; 2003 Jan; 98(1):151-9. PubMed ID: 12526951
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Reactivation of hepatitis and lamivudine therapy in 11 HBsAg-positive renal allograft recipients: a single centre experience.
    Murakami R; Amada N; Sato T; Orii T; Kikuchi H; Haga I; Ohashi Y; Okazaki H
    Clin Transplant; 2006; 20(3):351-8. PubMed ID: 16824154
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus.
    Perrillo R; Hann HW; Mutimer D; Willems B; Leung N; Lee WM; Moorat A; Gardner S; Woessner M; Bourne E; Brosgart CL; Schiff E
    Gastroenterology; 2004 Jan; 126(1):81-90. PubMed ID: 14699490
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Determinants of early mortality and benefits of lamivudine therapy in patients with hepatitis B virus-related decompensated liver cirrhosis.
    Tseng PL; Lu SN; Tung HD; Wang JH; Changchien CS; Lee CM
    J Viral Hepat; 2005 Jul; 12(4):386-92. PubMed ID: 15985009
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Discontinuation of lamivudine treatment for hepatitis flare after kidney or heart transplantation in hepatitis B surface antigen-positive patients: A retrospective case series.
    Huang YW; Liu CJ; Lai MY; Lee PH; Tsai MK; Wang SS; Lai MK; Kao JH
    Clin Ther; 2006 Sep; 28(9):1327-34. PubMed ID: 17062306
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Association of lamivudine resistance in recurrent hepatitis B after liver transplantation with advanced hepatic fibrosis.
    Ben-Ari Z; Pappo O; Zemel R; Mor E; Tur-Kaspa R
    Transplantation; 1999 Jul; 68(2):232-6. PubMed ID: 10440393
    [TBL] [Abstract][Full Text] [Related]  

  • 35. High pre-treatment serum hepatitis B virus titre predicts failure of lamivudine prophylaxis and graft re-infection after liver transplantation.
    Mutimer D; Pillay D; Dragon E; Tang H; Ahmed M; O'Donnell K; Shaw J; Burroughs N; Rand D; Cane P; Martin B; Buchan S; Boxall E; Barmat S; Gutekunst K; McMaster P; Elias E
    J Hepatol; 1999 Apr; 30(4):715-21. PubMed ID: 10207815
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prevention and risk factors of the HBV recurrence after orthotopic liver transplantation: 160 cases follow-up study.
    Xie SB; Zhu JY; Ying Z; Zeng LJ; Chao M; Lu MQ
    Transplantation; 2010 Oct; 90(7):786-90. PubMed ID: 20703179
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy of lamivudine in chronic hepatitis B patients with active viral replication and decompensated cirrhosis undergoing liver transplantation.
    Bain VG; Kneteman NM; Ma MM; Gutfreund K; Shapiro JA; Fischer K; Tipples G; Lee H; Jewell LD; Tyrrell DL
    Transplantation; 1996 Nov; 62(10):1456-62. PubMed ID: 8958272
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Study on the efficacy and safety of adefovir dipivoxil treatment in post-liver transplant patients with hepatitis B virus infection and lamivudine-resistant hepatitis B virus.
    Bárcena R; Del Campo S; Moraleda G; Casanovas T; Prieto M; Buti M; Moreno JM; Cuervas V; Fraga E; De la Mata M; Otero A; Delgado M; Loinaz C; Barrios C; Dieguez ML; Mas A; Sousa JM; Herrero JI; Muñoz R; Avilés JF; Gonzalez A; Rueda M
    Transplant Proc; 2005 Nov; 37(9):3960-2. PubMed ID: 16386596
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation.
    Bartholomew MM; Jansen RW; Jeffers LJ; Reddy KR; Johnson LC; Bunzendahl H; Condreay LD; Tzakis AG; Schiff ER; Brown NA
    Lancet; 1997 Jan; 349(9044):20-2. PubMed ID: 8988118
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Precore stop codon mutation of hepatitis B virus is associated with low breakthrough rate following long-term lamivudine therapy.
    Shin JW; Chung YH; Choi MH; Kim JA; Ryu SH; Jang MK; Kim IS; Park NH; Lee HC; Lee YS; Suh DJ
    J Gastroenterol Hepatol; 2005 Jun; 20(6):844-9. PubMed ID: 15946130
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.